Immunome (NASDAQ:IMNM) Rating Reiterated by Wedbush

Wedbush reissued their outperform rating on shares of Immunome (NASDAQ:IMNM) in a research note released on Thursday morning, RTT News reports. They currently have a $33.00 target price on the stock.

Several other research analysts also recently issued reports on the stock. Guggenheim assumed coverage on shares of Immunome in a research report on Monday, April 15th. They set a buy rating and a $35.00 price target on the stock. Piper Sandler assumed coverage on shares of Immunome in a research report on Friday, May 31st. They set an overweight rating and a $27.00 price target on the stock. Finally, JPMorgan Chase & Co. assumed coverage on shares of Immunome in a research report on Tuesday, April 30th. They set an overweight rating and a $24.00 price target on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of Buy and a consensus price target of $29.80.

Immunome Price Performance

Shares of Immunome stock opened at $16.51 on Thursday. The company’s fifty day moving average price is $13.81 and its two-hundred day moving average price is $17.62. Immunome has a 52-week low of $6.13 and a 52-week high of $30.96. The firm has a market capitalization of $990.10 million, a PE ratio of -2.19 and a beta of 1.79.

Immunome (NASDAQ:IMNM) last posted its earnings results on Tuesday, May 14th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.46. Immunome had a negative net margin of 1,829.44% and a negative return on equity of 37.33%. The business had revenue of $1.03 million for the quarter, compared to analyst estimates of $4.00 million. Analysts predict that Immunome will post -1.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Immunome

In other Immunome news, Director Jean Jacques Bienaime bought 2,000 shares of the business’s stock in a transaction on Tuesday, May 21st. The shares were bought at an average cost of $13.57 per share, for a total transaction of $27,140.00. Following the transaction, the director now owns 9,615 shares in the company, valued at approximately $130,475.55. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 8.60% of the company’s stock.

Institutional Trading of Immunome

Hedge funds have recently modified their holdings of the company. Avidity Partners Management LP acquired a new stake in shares of Immunome in the 4th quarter valued at approximately $14,268,000. Cerity Partners LLC acquired a new stake in shares of Immunome in the 4th quarter valued at approximately $656,000. Mayo Clinic acquired a new stake in shares of Immunome in the 4th quarter valued at approximately $1,161,000. Lord Abbett & CO. LLC acquired a new stake in shares of Immunome in the 1st quarter valued at approximately $10,994,000. Finally, Swiss National Bank acquired a new stake in shares of Immunome in the 1st quarter valued at approximately $1,762,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.